We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+13.76%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.69B
AUM Growth
+$332M
Cap. Flow
+$42.5M
Cap. Flow %
1.15%
Top 10 Hldgs %
69.25%
Holding
31
New
4
Increased
15
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$42M
2
JUNO
Juno Therapeutics, Inc.
JUNO
+$23.9M
3
KITE
Kite Pharma, Inc.
KITE
+$20M
4
CEMP
Cempra, Inc.
CEMP
+$19.2M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$18.1M

Top Sells

Rank Stock Value
1
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$100M
2
IMGN
Immunogen Inc
IMGN
+$25.4M
3
GILD icon
Gilead Sciences
GILD
+$16.4M
4
INVA icon
Innoviva
INVA
+$8.59M
5
HALO icon
Halozyme
HALO
+$6.08M

Sector Composition

Rank Sector Weight
1 Healthcare 82.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$413M 11.18%
3,564,298
+10,000
+0.3% +$1.14M
INCY icon
2
Incyte
INCY
$25.3B
$390M 10.57%
3,740,406
-51,461
-1% -$5.33M
IONS icon
3
Ionis Pharmaceuticals
IONS
$9.08B
$341M 9.25%
5,929,426
+200,000
+3% +$12.7M
GILD icon
4
Gilead Sciences
GILD
$166B
$318M 8.62%
2,715,596
-150,000
-5% -$16.4M
RDUS
5
DELISTED
Radius Health, Inc.
RDUS
$266M 7.2%
3,922,140
+200,000
+5% +$9.32M
AGIO icon
6
Agios Pharmaceuticals
AGIO
$2.1B
$221M 6%
1,989,921
+140,000
+8% +$15.1M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$125B
$165M 4.47%
1,334,445
– –
NBIX icon
8
Neurocrine Biosciences
NBIX
$18.3B
$154M 4.17%
3,221,552
+20,000
+0.6% +$848K
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
$147M 4%
2,581,112
+31,700
+1% +$1.95M
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$141M 3.81%
777,428
+105,000
+16% +$18.1M
HALO icon
11
Halozyme
HALO
$9.87B
$137M 3.72%
6,077,168
-346,202
-5% -$6.08M
RCPT
12
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$126M 3.43%
665,272
+30,000
+5% +$4.96M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.5B
$116M 3.14%
965,499
+130,000
+16% +$15.5M
REGN icon
14
Regeneron Pharmaceuticals
REGN
$72.8B
$101M 2.74%
198,000
– –
NVAX icon
15
Novavax
NVAX
$1.2B
$91.1M 2.47%
409,000
-13,500
-3% -$2.37M
TTPH
16
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$71.5M 1.94%
75,356
+1,500
+2% +$1.23M
ALDR
17
DELISTED
Alder Biopharmaceuticals
ALDR
$61.2M 1.66%
+1,155,150
New +$42M
PBYI icon
18
Puma Biotechnology
PBYI
$397M
$60.9M 1.65%
521,991
– –
CEMP
19
DELISTED
Cempra, Inc.
CEMP
$60.7M 1.65%
1,766,900
+543,900
+44% +$19.2M
PTCT icon
20
PTC Therapeutics
PTCT
$6.2B
$60.3M 1.63%
1,252,912
+75,000
+6% +$4.38M
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$54.3M 1.47%
618,188
– –
TSRO
22
DELISTED
TESARO, Inc.
TSRO
$53.2M 1.44%
904,582
+50,000
+6% +$2.87M
ICPT
23
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$43.6M 1.18%
180,719
+25,719
+17% +$6.85M
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$29.6M 0.8%
2,700,737
+80,000
+3% +$1.03M
JUNO
25
DELISTED
Juno Therapeutics, Inc.
JUNO
$24M 0.65%
+450,000
New +$23.9M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q2 2015 Portfolio in Review

As of Q2 2015, BB Biotech held 31 positions worth $3.69B, up 9.9% from $3.36B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

BB Biotech's Q2 2015 filing shows 4 new, 15 increased, 5 reduced and 2 closed positions. Its largest new stake was Alder Biopharmaceuticals: 1,155,150 shares worth $61.2M. The largest sale was SYNAGEVA BIOPHARMA CORP COM STK (DE), an estimated $100M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier.

  • BB Biotech's largest Q2 2015 buy was Alder Biopharmaceuticals: 1,155,150 shares worth $61.2M.
  • BB Biotech added most to Cempra, Inc. in Q2 2015, an estimated $19.2M increase.
  • BB Biotech's biggest Q2 2015 reduction was Gilead Sciences, cutting an estimated $16.4M.
  • BB Biotech fully exited SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2015, selling an estimated $100M.
  • BB Biotech's ten largest holdings make up 69% of its $3.69B portfolio in Q2 2015.
  • BB Biotech opened 4 new positions and closed 2 in Q2 2015.
  • BB Biotech's portfolio value rose 9.9% quarter-over-quarter to $3.69B.

Based on BB Biotech's 13F filing for Q2 2015, filed 12 Aug 2015.